The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders

Pellegrino Musto; Fiorella D&apos;Auria

doi:10.1517/14712598.2011.567262

The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders

Pellegrino Musto, Fiorella D'Auria

IRCCS Centro di Riferimento Oncologico della Basilicata (CROB)

Research output: Contribution to journal › Article › peer-review

Abstract

Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic B-cells. Several mechanisms have been proposed to explain CD20 loss after rituximab therapy, while the clinical significance (if any) of this phenomenon is still not clear. We have produced a brief overview of the biological aspects of CD20 modulation after rituximab treatment and its possible clinical implications.

Original language	English
Pages (from-to)	551-557
Number of pages	7
Journal	Expert Opinion on Biological Therapy
Volume	11
Issue number	5
DOIs	https://doi.org/10.1517/14712598.2011.567262
Publication status	Published - May 2011

Keywords

Anti-CD20 monoclonal antibodies
CD20 antigen
CD20 modulation
chronic lymphocytic leukemia
non-Hodgkin's lymphoma
Richter's syndrome
rituximab

ASJC Scopus subject areas

Pharmacology
Clinical Biochemistry
Drug Discovery

Access to Document

10.1517/14712598.2011.567262

Fingerprint Dive into the research topics of 'The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders'. Together they form a unique fingerprint.

Cite this

The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders. / Musto, Pellegrino; D'Auria, Fiorella.

In: Expert Opinion on Biological Therapy, Vol. 11, No. 5, 05.2011, p. 551-557.

Research output: Contribution to journal › Article › peer-review

@article{60bca9063a494d9dbe0fc9160089df9d,

title = "The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders",

abstract = "Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic B-cells. Several mechanisms have been proposed to explain CD20 loss after rituximab therapy, while the clinical significance (if any) of this phenomenon is still not clear. We have produced a brief overview of the biological aspects of CD20 modulation after rituximab treatment and its possible clinical implications.",

keywords = "Anti-CD20 monoclonal antibodies, CD20 antigen, CD20 modulation, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Richter's syndrome, rituximab",

author = "Pellegrino Musto and Fiorella D'Auria",

year = "2011",

month = may,

doi = "10.1517/14712598.2011.567262",

language = "English",

volume = "11",

pages = "551--557",

journal = "Expert Opinion on Biological Therapy",

issn = "1471-2598",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders

AU - Musto, Pellegrino

AU - D'Auria, Fiorella

PY - 2011/5

Y1 - 2011/5

N2 - Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic B-cells. Several mechanisms have been proposed to explain CD20 loss after rituximab therapy, while the clinical significance (if any) of this phenomenon is still not clear. We have produced a brief overview of the biological aspects of CD20 modulation after rituximab treatment and its possible clinical implications.

AB - Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic B-cells. Several mechanisms have been proposed to explain CD20 loss after rituximab therapy, while the clinical significance (if any) of this phenomenon is still not clear. We have produced a brief overview of the biological aspects of CD20 modulation after rituximab treatment and its possible clinical implications.

KW - Anti-CD20 monoclonal antibodies

KW - CD20 antigen

KW - CD20 modulation

KW - chronic lymphocytic leukemia

KW - non-Hodgkin's lymphoma

KW - Richter's syndrome

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=79953875843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953875843&partnerID=8YFLogxK

U2 - 10.1517/14712598.2011.567262

DO - 10.1517/14712598.2011.567262

M3 - Article

C2 - 21385115

AN - SCOPUS:79953875843

VL - 11

SP - 551

EP - 557

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 5

ER -